| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1037413493 |
| P356 | DOI | 10.1186/1745-6150-5-24 |
| P932 | PMC publication ID | 2885348 |
| P698 | PubMed publication ID | 20406442 |
| P5875 | ResearchGate publication ID | 43226387 |
| P2093 | author name string | Yang Kuang | |
| John D Nagy | |||
| Steffen E Eikenberry | |||
| P2860 | cites work | Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase | Q73025259 |
| Identification of androgen-responsive genes in the rat ventral prostate by complementary deoxyribonucleic acid subtraction and microarray | Q73133779 | ||
| Castration-induced apoptotic cell death in the Brown Norway rat prostate decreases as a function of age | Q73392868 | ||
| Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group | Q73761091 | ||
| Exploring the relationship between neutral and selective mutations in cancer | Q73870494 | ||
| Age-dependent and lobe-specific spontaneous hyperplasia in the brown Norway rat prostate | Q77437368 | ||
| On the prevention and therapy of prostate cancer by androgen administration | Q78257199 | ||
| Darwinian medicine: a case for cancer | Q79777489 | ||
| Protein profiling of rat ventral prostate following chronic finasteride administration: identification and localization of a novel putative androgen-regulated protein | Q79892880 | ||
| Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score | Q80212568 | ||
| Hormonal pattern in prostatic cancer. II. Correlation with primary response to endocrine treatment | Q38577108 | ||
| Hormonal predictors of prostate cancer | Q39804755 | ||
| Binding properties of androgen receptors. Evidence for identical receptors in rat testis, epididymis, and prostate | Q40015268 | ||
| Antiandrogens prevent stable DNA-binding of the androgen receptor | Q40377668 | ||
| Prognostic factors in metastatic prostate cancer | Q40384473 | ||
| Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft | Q40503174 | ||
| Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. | Q40812297 | ||
| Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells | Q40905901 | ||
| Regulation of prostate growth by fibroblast growth factors | Q40958229 | ||
| Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group | Q41159314 | ||
| Prognostic value of serum hormone concentrations in prostatic cancer | Q41410732 | ||
| Long-term effects of finasteride on prostate tissue composition | Q41617018 | ||
| Autologous down-regulation of androgen receptor messenger ribonucleic acid | Q41749647 | ||
| The relationship between adrogen receptors and the hormonally controlled responses of rat ventral prostate | Q41883723 | ||
| Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland | Q43545784 | ||
| High-grade prostate cancer is associated with low serum testosterone levels | Q43576700 | ||
| Increased androgen receptor expression correlates with development of age-dependent, lobe-specific spontaneous hyperplasia of the brown Norway rat prostate | Q43715848 | ||
| A cellular automaton model of early tumor growth and invasion | Q43816899 | ||
| Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer | Q43853411 | ||
| Gene expression profiling of androgen deficiency predicts a pathway of prostate apoptosis that involves genes related to oxidative stress. | Q44226051 | ||
| Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy | Q44398102 | ||
| The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models | Q44521050 | ||
| High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study | Q44675825 | ||
| Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy | Q45269738 | ||
| A worse prognosis for men with testicular atrophy at therapeutic orchiectomy for prostate carcinoma | Q46042589 | ||
| Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. | Q46200270 | ||
| Prostate volume and adverse prostate cancer features: fact not artifact | Q46904796 | ||
| Circulating steroid hormones and the risk of prostate cancer | Q46910105 | ||
| Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study | Q47364687 | ||
| Mathematical model for the androgenic regulation of the prostate in intact and castrated adult male rats | Q48508126 | ||
| Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free, primary cell culture | Q48678491 | ||
| Evolutionary biology of cancer. | Q51727179 | ||
| Prognostic factors in patients with advanced prostate cancer. | Q52533039 | ||
| Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. | Q52534321 | ||
| Why don't all whales have cancer? A novel hypothesis resolving Peto's paradox. | Q53330521 | ||
| Cancer selection. | Q53382154 | ||
| Low Androgen Levels Induce the Development of Androgen-Hypersensitive Cell Clones in Shionogi Mouse Mammary Carcinoma Cells in Culture | Q54376528 | ||
| Origin of the resistance of leukaemic cells to folic acid antagonists. | Q54747803 | ||
| Regulation of androgen receptor protein and mRNA concentrations by androgens in rat ventral prostate and seminal vesicles and in human hepatoma cells | Q68494436 | ||
| Androgen receptor dynamics in the rat ventral prostate | Q68942357 | ||
| A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells | Q69499299 | ||
| Pre-treatment testosterone levels: significance in androgen deprivation therapy | Q70309870 | ||
| Carcinoma of the prostate: relationship of pretreatment hormone levels to survival | Q70479618 | ||
| Blockade of androstenedione-induced stimulation of androgen-sensitive parameters in the rat prostate by combination of Flutamide and 4-MA | Q70659234 | ||
| Evidence for atrophy and apoptosis in the prostates of men given finasteride | Q71091964 | ||
| Androgen receptor protein in the androgen-dependent Dunning R-3327 prostate carcinoma | Q71432225 | ||
| Autoregulation of androgen receptor protein and messenger RNA in rat ventral prostate is protein synthesis dependent | Q71779570 | ||
| Autologous Regulation of Androgen Receptor Messenger Ribonucleic Acid in the Separate Lobes of the Rat Prostate Gland1 | Q71787814 | ||
| Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells | Q71934138 | ||
| Age- and lobe-specific responses of the brown Norway rat prostate to androgen | Q72404122 | ||
| Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride | Q72458798 | ||
| Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma | Q72751447 | ||
| Cancer as an evolutionary and ecological process | Q22122026 | ||
| 5-alpha-reductase inhibitors for prostate cancer prevention | Q22252970 | ||
| Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat | Q24561881 | ||
| Compartmentalization of androgen receptor protein-protein interactions in living cells | Q24683283 | ||
| Cancer statistics, 2008 | Q27860585 | ||
| Molecular determinants of resistance to antiandrogen therapy | Q28236889 | ||
| The clonal evolution of tumor cell populations | Q28271546 | ||
| Why do cancers have high aerobic glycolysis? | Q28290710 | ||
| Characterization and expression of a cDNA encoding the human androgen receptor | Q28360106 | ||
| Tissue distribution and kinetic characteristics of rat steroid 5 alpha-reductase isozymes. Evidence for distinct physiological functions | Q28566245 | ||
| Androgen receptor in prostate cancer | Q29616454 | ||
| A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental data | Q30983127 | ||
| Sex hormones induce direct epithelial and inflammation-mediated oxidative/nitrosative stress that favors prostatic carcinogenesis in the noble rat. | Q33295021 | ||
| The broad spectrum of responses to oxidants in proliferating cells: a new paradigm for oxidative stress | Q33904259 | ||
| Macromolecular crowding: obvious but underappreciated | Q33955060 | ||
| Competition and natural selection in a mathematical model of cancer | Q33979247 | ||
| The dawn of Darwinian medicine | Q34119318 | ||
| Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. | Q34339362 | ||
| Genetic clonal diversity predicts progression to esophageal adenocarcinoma | Q34505745 | ||
| The influence of finasteride on the development of prostate cancer | Q34534815 | ||
| Prostate cancer risk in testosterone-treated men. | Q34582772 | ||
| Testosterone as a predictor of pathological stage in clinically localized prostate cancer | Q35758294 | ||
| Androgen receptor gene and hormonal therapy failure of prostate cancer | Q35764223 | ||
| Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers | Q35773657 | ||
| Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth | Q35843249 | ||
| Natural selection in neoplastic progression of Barrett's esophagus | Q36206969 | ||
| Mitochondrial reactive oxygen species are required for hypoxic HIF alpha stabilization. | Q36647216 | ||
| Genes regulated by androgen in the rat ventral prostate | Q36715055 | ||
| Correlations of dietary patterns with prostate health | Q37031998 | ||
| Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline | Q37403069 | ||
| The ecology and evolutionary biology of cancer: a review of mathematical models of necrosis and tumor cell diversity | Q37724745 | ||
| Alternative equilibria in shallow lakes | Q37828702 | ||
| Radical reactions in vivo--an overview | Q38027458 | ||
| P921 | main subject | mathematical model | Q486902 |
| P304 | page(s) | 24 | |
| P577 | publication date | 2010-04-20 | |
| P1433 | published in | Biology Direct | Q1954915 |
| P1476 | title | The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model | |
| P478 | volume | 5 |
| Q28483635 | A multiscale, mechanism-driven, dynamic model for the effects of 5α-reductase inhibition on prostate maintenance |
| Q37836264 | Androgen regulation of prostate cancer: where are we now? |
| Q38683022 | Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients' data with prostatic diseases |
| Q28741953 | Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors |
| Q38382669 | Cell line modeling to study biomarker panel in prostate cancer |
| Q42786557 | Evolution and cancer: a mathematical biology approach |
| Q92140133 | Mathematical Models of Cancer: When to Predict Novel Therapies, and When Not to |
| Q35621205 | Mathematical modeling of prostate cancer progression in response to androgen ablation therapy |
| Q36574383 | Prediction of treatment efficacy for prostate cancer using a mathematical model |
| Q27331671 | Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer |
| Q39433008 | Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression |
Search more.